Editas Medicine announced the start of a Phase 1/2 clinical trial for its gene-editing drug EDIT-401 targeting hyperlipidemia, with regulatory approval received in Australia. Preclinical data showed EDIT-401 can reduce LDL cholesterol by over 90% for 10 months, highlighting its potential as a one-time transformative treatment. The company expects to begin patient dosing in 2026 and report initial safety data in early 2027, with topline results expected in late 2027. Editas also secured milestone payments through its collaboration with Bristol Myers Squibb and has a cash runway into the second half of 2028 to support ongoing development.
Editas Medicine's gene-editing drug development is highlighted alongside Pluang's Health sector market data. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 18:41 WIB: out of 150 priced US health stocks, 108 rose and 26 fell today. Notable movers include NUWE at USD 4.74 (+3.49%), CTXR at USD 0.54 (-2.98%), and HIMS at USD 25.29 (-2.73%).
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
